This section provides you with a selection of expert opinions from leaders in the field.
You will find interviews with CML experts providing their personal perspectives on highlights from scientific meetings and latest scientific advancements as well as keynote presentations from iCMLf prize winners. The topics featured cover a broad range of issues from CML science to clinical practice.
Professor Susan Branford
Centre for Cancer Biology & SA Pathology, Adelaide, Australia
The 2022 iCMLf prize winners have been awarded their prizes during the 24th John Goldman Conference on CML in Mandelieu (France). After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.
![]() |
|
The 2021 iCMLf prize winners have been awarded their prizes during the 23nd John Goldman E-Conference on CML. After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.
![]() |
|
At the 22nd John Goldman E-Conference on CML the 2020 iCMLf prize winners have been awarded their prizes. During keynote presentations the prize recipients shared personal perspectives on their scientific and clinical work for CML over the past years. You can view web streams of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.
![]() |
|
At the 21th Annual John Goldman Conference on CML in Bordeaux the iCMLf Directors awarded the Foundation’s 2019 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the Rowley Prize and the iCMLf Prize keynote presentations here. Unfortunately François-Xavier Mahon's presentation on 'Curing CML: To be, or not to be, that is the question' (Goldman Prize) is not available as a web stream.
![]() |
|
Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
Georgia Cancer Center
Augusta University, Augusta (USA)
{rscomments off}
Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany)
We apologize for the background noise in this video.
{rscomments off}
At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session.
These summaries are brought to you with support from Bristol Myers Squibb.
In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.
Download the scientific summary report here
Professor Jane Apperley
Imperial College London, London, UK
Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.
Professor Timothy Hughes
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
Tim Hughes explored the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontination. He also discussed the facts that influence the choice of TKI when molecular responses are not optimal and highlighted the critical role of molecular monitoring in managaging treatment-free remission.
Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.
In Spanish:
Perspectivas sobre los estudios de discontinuación de terapia que se mostraron
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina
Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)
{rscomments off}
Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany)
{rscomments off}
In Spanish:
Perspectivas sobre nuevas estudios clínicos y cómo se transfieren al mundo real - especialmente en países en vía de desarollo
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina
Perspectives on biology and clinical aspects
from Professor Jorge Cortes
MD Anderson Cancer Center
University of Texas, Houston (USA)
At the 19th Annual John Goldman Conference on CML in Estoril the iCMLf Directors awarded the Foundation’s 2017 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.
At Tessa’s request, her keynote was presented by Mhairi Copland, Professor of Translational Haematology at the Paul O’ Gorman Leukemia Research Center at the University of Glasgow.
Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia
from Professor Jerry Radich
Fred Hutchinson Cancer Research Center
Seattle, USA
This independent educational resource is supported by a grant from Novartis Oncology
Perspectives on molecular monitoring in CML from
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia
Page 1 of 2